In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $179.11 in the prior trading day, Charles River Laboratories International Inc (NYSE: CRL) closed at $180.07, up 0.54%. In other words, the price has increased by $0.54 from its previous closing price. On the day, 0.95 million shares were traded. CRL stock price reached its highest trading level at $181.56 during the session, while it also had its lowest trading level at $178.17.
Ratios:
Our goal is to gain a better understanding of CRL by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 48.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.32. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.83.
On October 02, 2025, Barclays Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $195.
Jefferies Upgraded its Hold to Buy on September 09, 2025, while the target price for the stock was maintained at $195.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 22 ’25 when Joseph LaPlume bought 400 shares for $152.50 per share.
LaPlume Joseph W sold 800 shares of CRL for $126,080 on Aug 18 ’25. The EVP, Corp Strategy & Develop now owns 24,116 shares after completing the transaction at $157.60 per share. On Aug 18 ’25, another insider, WALLMAN RICHARD F, who serves as the Former Director of the company, bought 22,500 shares for $152.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRL now has a Market Capitalization of 8861997056 and an Enterprise Value of 11514407936. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.20 while its Price-to-Book (P/B) ratio in mrq is 2.64. Its current Enterprise Value per Revenue stands at 2.858 whereas that against EBITDA is 12.048.
Stock Price History:
The Beta on a monthly basis for CRL is 1.53, which has changed by -0.013206899 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, CRL has reached a high of $230.02, while it has fallen to a 52-week low of $91.86. The 50-Day Moving Average of the stock is 7.83%, while the 200-Day Moving Average is calculated to be 16.39%.
Shares Statistics:
The stock has traded on average 964.00K shares per day over the past 3-months and 1142460 shares per day over the last 10 days, according to various share statistics. A total of 49.21M shares are outstanding, with a floating share count of 48.66M. Insiders hold about 1.12% of the company’s shares, while institutions hold 103.21% stake in the company. Shares short for CRL as of 1760486400 were 2087410 with a Short Ratio of 2.17, compared to 1757894400 on 2563173. Therefore, it implies a Short% of Shares Outstanding of 2087410 and a Short% of Float of 4.8800003.
Earnings Estimates
At present, 14.0 analysts are actively evaluating the performance of Charles River Laboratories International Inc (CRL) in the stock market.The consensus estimate for the next quarter is $2.38, with high estimates of $2.52 and low estimates of $2.23.
Analysts are recommending an EPS of between $10.48 and $10.0 for the fiscal current year, implying an average EPS of $10.19. EPS for the following year is $10.77, with 17.0 analysts recommending between $11.72 and $9.45.
Revenue Estimates
11 analysts predict $990.79M in revenue for . The current quarter. It ranges from a high estimate of $1.01B to a low estimate of $979M. As of . The current estimate, Charles River Laboratories International Inc’s year-ago sales were $1.01BFor the next quarter, 11 analysts are estimating revenue of $985.56M. There is a high estimate of $1B for the next quarter, whereas the lowest estimate is $974.7M.
A total of 15 analysts have provided revenue estimates for CRL’s current fiscal year. The highest revenue estimate was $4.05B, while the lowest revenue estimate was $3.94B, resulting in an average revenue estimate of $3.99B. In the same quarter a year ago, actual revenue was $4.05BBased on 15 analysts’ estimates, the company’s revenue will be $4.09B in the next fiscal year. The high estimate is $4.17B and the low estimate is $4B.
